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Background: Opioids are the most frequently used drugs to treat pain in cancer patients. 
In some patients, however, opioids can cause adverse effects and drug–drug interactions. 
No advice concerning the combination of opioids and other drugs is given in the current 
European guidelines.
Objective: To identify studies that report clinically significant drug–drug interactions involving 
opioids used for pain treatment in adult cancer patients.
Design and data sources: Systematic review with searches in Embase, MEDLINE, and 
Cochrane Central Register of Controlled Trials from the start of the databases (Embase from 
1980) through January 2014. In addition, reference lists of relevant full-text papers were hand-
searched.
Results: Of 901 retrieved papers, 112 were considered as potentially eligible. After full-text 
reading, 17 were included in the final analysis, together with 15 papers identified through hand-
searching of reference lists. All of the 32 included publications were case reports or case series. 
Clinical manifestations of drug–drug interactions involving opioids were grouped as follows: 
1) sedation and respiratory depression, 2) other central nervous system symptoms, 3) impairment 
of pain control and/or opioid withdrawal, and 4) other symptoms. The most common mechanisms 
eliciting drug–drug interactions were alteration of opioid metabolism by inhibiting the activity of 
cytochrome P450 3A4 and pharmacodynamic interactions due to the combined effect on opioid, 
dopaminergic, cholinergic, and serotonergic activity in the central nervous system.
Conclusion: Evidence for drug–drug interactions associated with opioids used for pain treatment 
in cancer patients is very limited. Still, the cases identified in this systematic review give some 
important suggestions for clinical practice. Physicians prescribing opioids should recognize the 
risk of drug–drug interactions and if possible avoid polypharmacy.
Keywords: opioids, pain, cancer patients, drug–drug interactions
Introduction
Opioid analgesics are the most frequently used drugs to treat pain in patients with 
cancer.1 In some patients, however, opioids cause adverse effects.2 The most frequent 
adverse effects in cancer patients treated for pain with opioids are sedation, nausea/
vomiting, and constipation, but other infrequent adverse effects, such as myoclonus, 
hallucination, and respiratory depression, are also feared.1–3 Adverse drug reactions 
from opioids are most often caused by the opioid itself, but can also be a result of the 
combination of the opioid and another drug, a drug–drug interaction (DDI).4 The risk of 
DDIs is high in cancer patients because of the large number of concomitant drugs.5
DDIs can be categorized as pharmacokinetic, that is, one drug influences the phar-
macokinetic properties – absorption, distribution, metabolism, or excretion – of another 
Correspondence: Aleksandra Kotlinska-
Lemieszek
Osiedle Rusa 55, 61-245 Poznan, Poland
Tel +48 60 807 9698
Fax +48 61 873 8303
email alemieszek@ump.edu.pl 
Journal name: Drug Design, Development and Therapy
Article Designation: Review
Year: 2015
Volume: 9
Running head verso: Kotlinska-Lemieszek et al
Running head recto: Drug–drug interactions involving opioids in cancer patients
DOI: http://dx.doi.org/10.2147/DDDT.S86983
Drug Design, Development and Therapy 2015:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
5256
Kotlinska-Lemieszek et al
drug. DDIs can also be pharmacodynamic, when the effects 
of two drugs either potentiate or antagonize each other.6
DDIs are reported to lead to serious adverse drug reactions 
in patients treated with opioids for pain.7,8 Still, no advice 
concerning the combination of opioids and other drugs is 
given in the current guidelines.2 Some studies have assessed 
the number of potentially harmful drug combinations in 
cancer pain patients, but do not report the number of clinically 
observed adverse drug reactions actually resulting from such 
combinations.5,9 Thus, the real risk of clinically important DDIs 
related to opioid therapy in cancer patients is not established.
The lack of advice on drug combinations in current 
guidelines may be a result of this limited clinical information. 
Therefore, a systematic review of the literature is indicated 
to identify studies that report clinically relevant DDIs associ-
ated with opioid analgesics used for the treatment of pain in 
patients with cancer.
Methods
Search strategy
Systematic searches were performed in Embase and 
MEDLINE through OvidSP and in the Cochrane Central 
Register of Controlled Trials, from set up of the databases 
(Embase from 1980) through January 2014. The last day 
searched was March 14, 2014. The full search string for 
Embase is presented in Table 1. Titles and abstracts of the 
retrieved citations were reviewed independently by two of 
the researchers (DFH, AKL), and potentially relevant papers 
were read in full text (DFH, AKL). In cases of doubt or dis-
agreement, papers were reassessed by all three investigators 
(DFH, AKL, PK).
Additionally, reference lists of all the papers read in full 
text were hand-searched for relevant papers.
inclusion criteria
–	 Publications reporting clinically significant DDIs involv-
ing WHO step II or step III opioids, as assessed by the 
authors.
–	 The DDI observed in one or more adult patients with a 
diagnosis of malignant disease and treated with an opioid 
for pain.
–	 Any type of publication: randomized controlled trial, 
other controlled study, observational study, case report, 
case series, or letter to the Editor, except for publications 
available only in abstract form.
–	 Publications in English language.
exclusion criteria
–	 Experimental studies.
–	 Nonhuman studies.
–	 Only pharmacokinetic investigations (no clinical 
outcome).
–	 Studies in noncancer patients.
–	 Opioids used for indications other than pain or 
perioperatively.
–	 Duplicate publications.
Content analysis
The identified publications were grouped according to 
clinical presentation and probable underlying mechanism 
of the DDI. The DDIs and underlying mechanisms were 
presented as assessed and interpreted by the authors in each 
publication.
Results
Systematic review of the literature
After removal of duplicates, 901 papers were retrieved 
(Figure 1). A total of 112 of these papers were considered 
potentially eligible for inclusion. After reading the full-text 
papers, 17 publications were included in the final analysis. 
In addition, 15 relevant papers were identified through 
hand-searching the reference lists of the articles read in full 
text, adding up to a total number of 32 included publications 
(Table 2).10–41 Additionally, two papers that commented on 
two of the included publications were identified,42,43 but not 
included as cases in the review.
No randomized controlled trials or other controlled 
studies were found. All of the included publications were 
case reports or case series, reporting on 2–19 patients. Nine 
of the papers were published in the period 1983–2000, and 
23 in the period 2001–January 2014 (Table 2). In some 
case series, DDIs in both cancer patients and patients with 
Table 1 Search strategy
Search strategy in Embase for drug–drug interactions (DDIs) involving opioid analgesics used for pain treatment in cancer patients 
(#1 or #2 or #3)
#1 (exp opiate agonist/it or exp narcotic analgesic agent/it or exp narcotic agent/it or exp morphine derivative/it) and exp neoplasm/
#2 (exp opiate agonist/or exp narcotic analgesic agent/or exp narcotic agent/or exp morphine derivative/) and exp neoplasm/and (drug interaction/or 
drug antagonism/or drug competition/or drug inhibition/or drug potentiation/) and (exp pain/or analgesia/or analgesic activity/or pain relief/)
#3 (exp opiate agonist/or exp narcotic analgesic agent/or exp narcotic agent/or exp morphine derivative/) and exp neoplasm/and polypharmacy/
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nonmalignant diseases were reported.11,12,18,41 From these 
case series, only cases of DDIs due to opioids in patients 
with a diagnosis of malignant disease treated for pain were 
included in the review.
Opioids involved in DDis
The majority of included publications report DDIs related to 
opioids that are in common clinical use (Table 2):
–	 morphine, administered by various routes; oral, sub-
cutaneous, intravenous, epidural, and intrathecal (nine 
publications),14–22
–	 fentanyl, transdermal, and intravenous (nine publications,27–35 
of which seven described DDIs associated with transder-
mal preparations),
–	 oral methadone (six publications),16,37–41
–	 oral oxycodone (three publications),24–26
–	 tramadol combined with pethidine,10 tapentadol,13 
hydromorphone,23 and buprenorphine36 was reported in 
one paper each.
Four publications report DDIs associated with opioids 
of minor current clinical relevance: propoxyphene, dextro-
propoxyphene, and nalbuphine.11,12,15,16
Clinical presentation of DDis
Eleven papers reported DDIs resulting in sedation and respi-
ratory depression.18,19,22,24,30,32,36–40 Fifteen papers reported 
DDIs causing various other central nervous system (CNS) 
symptoms, including delirium,10,20,23–25,29,31,34–36 serotonin 
syndrome,25,26,35 myoclonus,14,29,35 hyperalgesia,14 extrapy-
ramidal symptoms,21 catatonia,10 neuroleptic malignant 
syndrome,34 or carbamazepine toxicity.11,12 Seven papers 
reported DDIs causing impairment of pain control and/or opi-
oid withdrawal.15–17,24,27,28,33 Finally, in three publications, other 
symptoms believed to be associated with opioid-related DDIs 
were reported: hypertension,13 hypotension,24 vomiting,24 
sweating,24 ventricular tachycardia/torsades de pointes.41
Mechanisms underlying DDis of opioids 
used for pain treatment in cancer 
patients
The mechanisms underlying DDIs involving opioid anal-
gesics used for pain treatment in patients with cancer in 
the publications included in this review are presented in 
Table 3.
Quality of evidence
The included studies have several limitations. Only case 
reports and case series were identified (Table 2). Most 
of the reports included in this review provide poor level 
of evidence. Some may also not represent true DDIs, but 
other opioid-related complications. However, we decided 
to include the reports as they were clinically evaluated and 
presented by the authors and published by the respective 
journals.
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Figure 1 PRISMA flow chart showing the selection of papers.
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Discussion
Evidence for DDIs involving opioids used for pain treatment 
in cancer patients is very limited. This systematic review of 
publications on clinically significant DDIs involving opioid 
analgesics used for pain treatment in patients with cancer 
identified only case reports and case series (Table 2).10–41 As 
no systematic studies were identified, it was not possible to 
do any statistical analysis.
The three major categories of DDIs identified in the 
review were increased opioid effects causing sedation and 
respiratory depression, other CNS toxicities, and decreased 
opioid effects causing more pain and/or acute withdrawal 
symptoms. The lack of controlled studies precludes specific 
conclusions on the risk of DDIs associated with opioids. 
Still, based upon the reported cases, it can be concluded that 
physicians treating patients for cancer pain should be aware 
of and closely monitor patients for DDIs.
The DDIs with increased opioid efficacy, resulting in seda-
tion and respiratory depression, were caused by decreased 
opioid metabolism,19,24,30,32,36–40 impaired renal excretion,22 or 
an additional therapy that also relieves pain and possesses 
sedative and respiratory depressant effect (eg, amitriptyline 
or intrathecal bupivacaine added to morphine)18,19 (Tables 2 
and 3). Most examples identified in the review refer to opioids 
metabolized by cytochrome P450 (CYP450), and cytochrome 
P450 izoenzyme CYP3A4 (CYP3A4) in particular, such as 
fentanyl, methadone, oxycodone, or buprenorphine, either 
by concomitant use of CYP3A4 substrates and inhibitors 
(voriconazole, fluconazole, clarithromycin, cimetidine, 
and sertraline) or by discontinuation of a CYP3A4 inducer 
(carbamazepine) (Tables 2 and 4).24,30,32,36–40,44 Morphine 
pharmacokinetics were reported to be affected by a DDI 
leading to sedation and respiratory depression only in two 
case reports.19,22 In one of these publications, morphine was 
coadministered with amitriptyline and ranitidine,19 two drugs 
which can affect morphine glucuronidation45,46 (Table 2). 
Morphine may also indirectly be affected by renal failure 
caused by another drug.22 Additionally, other drugs with 
sedative effects can cause pharmacodynamic DDIs with 
an opioid. A typical observation in clinical practice is the 
combination of an opioid and a benzodiazepine, both con-
tributing to sedation.
CNS symptoms (other than sedation and respiratory 
depression) associated with opioids included hyperactive or 
hypoactive delirium with or without hallucinations, serotonin 
toxicity, myoclonus, hyperalgesia, extrapyramidal symptoms, 
catatonia, and neuroleptic malignant syndrome (Table 2). 
CNS symptoms were related both to decreased clearance of 
an opioid due to decreased metabolism20,24,29,31,36 or impaired 
renal elimination23 and to a variety of interactions influ-
encing several biological systems in the CNS10,14,21,25,26,34,35 
(Table 3). Additionally, two reports presented cases of 
carbamazepine neurotoxicity related to inhibition of its 
metabolism by propoxyphene and dextropropoxyphene, opi-
oids with an inhibitory effect on cytochrome P450 enzymes 
(Table 2).11,12,47
DDIs involving opioids can cause acute exacerba-
tions of pain, or withdrawal symptoms (Table 2). In the 
identified cases, these symptoms resulted from the addi-
tion of an opioid with a mixed agonist–antagonist effect 
(nalbuphine),15,16 and increased or decreased metabolism of 
an opioid due to the coadministration of a CYP3A4 inducer 
(rifampin)27,28 or inhibitor (cyclosporine)33 or cessation 
of CYP3A4 inhibition (voriconazole)24 (Table 3). Nalbu-
phine, which is an agonist at kappa opioid receptors and an 
antagonist at mu opioid receptors,48 reverses the analgesic 
effect of mu opioid agonists when used concomitantly.15,16 
Rifampin is a potent inducer of metabolizing enzymes, 
including CYP3A4, and may enhance clearance and atten-
uate the clinical effects of opioids.27,28,49–53 The withdrawal 
syndrome reported after discontinuation of a low dose of 
transdermal fentanyl (25 µg/h) was attributed to increased 
blood concentration of fentanyl (and increased effect) due 
to coadministration of cyclosporine, a CYP3A4 inhibitor.33 
Additionally, one case series described impaired pain con-
trol in three patients who were given somatostatin as part 
of their antineoplastic treatment.17 The exact mechanism 
for this DDI is not certain. The authors suggest opioid 
antagonistic effect of somatostatin, demonstrated in animal 
studies.17,54
Table 3 Mechanisms underlying DDis involving opioid analgesics 
used for pain treatment in patients with cancer
Mechanisms underlying DDIs of opioid analgesics
Pharmacokinetic DDIs
1)  inhibition or induction of opioid metabolism through CYP450  
or other metabolizing enzymes19,20,24,27–33,36–41
2) Decreased renal elimination of an opioid22,23
3)  inhibition of the metabolism of other drugs exerted by an opioid11,12
Pharmacodynamic DDIs
1)  Potentiation of analgesic efficacy and toxicity through opioid and  
nonopioid mechanisms18,19
2)  inhibition or reversal of the effect of an opioid by antagonism at  
opioid receptors, or by other mechanisms15–17
3)  Modification of cholinergic, adrenergic, dopaminergic, and  
serotoninergic activity in the CNS10,13,14,25,26,34,35
Others (including DDis with unknown mechanism)21
Abbreviations: CNS, central nervous system; DDi, drug–drug interactions.
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Finally, some other important DDIs were identified 
(Table 2). Prolonged QT time and ventricular arrhythmias 
(torsades de pointes) were seen in a patient receiving a high 
dose of methadone, and at the same time, three drugs that 
were CYP3A4 substrates. The authors suggest that these 
coadministered drugs may have interfered with methadone 
metabolism and caused elevation of its level in the blood.41
Multiple complex mechanisms, often not fully understood, 
underlie DDIs involving opioid analgesics (Table 3). In this 
review, we refer to the mechanisms of DDIs as they were 
understood and presented by the authors. In some cases, alter-
native causes for the observed complications may be found.
The most frequently reported mechanism of DDIs was 
associated with cytochrome P450 enzyme activity. In our 
review, the implicated opioids were fentanyl, methadone, 
oxycodone, and buprenorphine.24,27–33,36–41 Of these, orally 
administered oxycodone and methadone have been shown 
to be more susceptible to DDIs related to CYP3A4 or 
other CYP enzymes in studies in volunteers,49,50,55–58 while 
fentanyl pharmacokinetics were less affected in volunteer 
studies.51,59–62 Still, DDIs of fentanyl associated with CYP3A4 
activity were reported in seven publications identified by 
this review.27–33
Buprenorphine metabolism can be increased by strong 
CYP3A4 inducers as demonstrated in a study with rifampin,52 
while the effect of CYP3A4 inhibitors is limited due to 
complex metabolism (conversion to norbuprenorphine by 
CYP3A4 and CYP2C8, and glucuronidation) as well as 
renal and extrarenal elimination of the parent drug and 
metabolites.50,63 As noted by Davis, the case report involv-
ing buprenorphine36 should probably be best interpreted as 
a result of rapid dose increase before time to maximum con-
centration or steady state was reached, and not a DDI.43
In our review, most drugs that precipitated serious 
CYP3A4-mediated DDIs (voriconazole, itraconazole, 
fluconazole, clarithromycin, diltiazem) are also drugs rele-
vant for patients with advanced cancer, supporting the clinical 
importance of this finding. The vast majority of DDIs occur 
after a precipitating drug is introduced. The opposite effect of 
a decreased or increased opioid action may be caused if the 
use of a CYP3A4 inhibitor or inducer is stopped,24,37 thereby 
decreasing or increasing the serum concentration of the drug 
(Table 4). Defining a consequence of stopping a drug as an 
interaction, is perhaps counterintuitive, but it still represents 
symptoms related to a pharmacokinetic DDI. Interactions are 
less frequent if an opioid is introduced in a patient already 
using another drug. This may be related to titration of the 
opioid dose to obtain the desired clinical effect. Thus, a DDI 
may change the dose, but not the clinical outcome.
In cancer patients, the coexistence of other clinical factors 
can increase the risk of DDIs (Table 2). Impaired renal function 
is a common predisposing factor of DDIs31,32 and has added 
importance in cancer pain management because the incidence 
of renal impairment in patients with advanced cancer is high.64,65 
Also, the concomitant use of other drugs and the frequent need 
to change coadministered drugs and their doses add to the 
complexity of DDIs of opioids in these patients.5,9
The presence of DDIs seems to be underreported. This 
lack of formal evidence may have several explanations. First, 
the DDI may not be detected, or the symptoms are believed to 
be caused by the cancer disease and, therefore, not recognized 
as drug related. Second, DDIs are mostly observed by clini-
cians, who often do not have the time, the experience, or the 
interest to publish clinical observations. Third, several DDIs, 
even if not reported in the literature, may be considered as 
frequent and part of common knowledge, and therefore, not 
Table 4 CYP3A4 enzyme inhibitors and inducers reported to have caused clinically significant drug–drug interactions with opioids 
metabolized by CYP3A4 (oxycodone, methadone, fentanyl) in papers included in the present review24,27–33,37–39,44
Drugs Effect on  
CYP3A4 activity
Resulting effects when  
coadministered with opioid
Resulting effects after  
withdrawal of interacting drug
CYP3A4 inhibitors
voriconazole Strong
Decreased rate of opioid metabolism,  
increased opioid effect, increased risk  
of opioid toxicity
increased opioid metabolism, 
decreased clinical effect of opioid
itraconazole Strong
Fluconazole Moderate
Clarithromycin Strong
Diltiazem Moderate
Cyclosporine weak
Cimetidine weak
CYP3A4 inducers
Rifampin
Carbamazepine
Strong
Strong
increased metabolism of opioid,  
requirement for higher opioid doses,  
deterioration of pain control
Decreased rate of opioid 
metabolism, increased risk of 
opioid overdose
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reported. Finally, many journals only occasionally publish 
case reports and, perhaps, case reports are more often pub-
lished in national journals and therefore not identified by a 
search strategy excluding non-English papers.
Conclusion
For obvious ethical reasons, there are no randomized 
controlled trials or other well-designed controlled studies 
exploring DDIs. Recommendations must therefore be based 
upon cases reporting serious adverse drug reactions and basic 
knowledge about drug mechanisms. The cases identified in 
this systematic review can give some suggestions for clini-
cal practice:
•	 The combined use of an opioid and another drug with 
CNS depressant effect (eg, amitriptyline) increases the 
risk of acute opioid toxicity and respiratory depression. 
Such drugs should be carefully titrated according to 
effect.
•	 Opioids with antagonistic effects at the mu opioid recep-
tor (eg, nalbuphine) should not be coadministered with 
another opioid analgesic.
•	 The concomitant use of an opioid and a drug, which 
affects the activity of cholinergic, dopaminergic, and/or 
serotonergic systems in the CNS (eg, selective serotonin 
inhibitors), can cause CNS-related complications (eg, 
delirium and serotonin syndrome) and should, therefore, 
be monitored carefully.
•	 Introduction of a CYP3A4 inhibitor in a patient treated 
with fentanyl, oxycodone, or methadone may result in 
opioid overdose and increased opioid toxicity (Table 4). 
Caution has to be undertaken when such drugs are 
implemented. The use of a major CYP450 inducer may 
impair pain treatment (Table 4). Opposite effects should 
be expected when these drugs are stopped (Table 4).
•	 Finally, the physician should recognize the risk for DDIs 
of opioids, monitor the patients carefully for interactions, 
and if possible avoid polypharmacy.
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